Optimizing Biologics In Order to Minimize the severe Asthma Burden (OBIOMAB).
Jacob Sont (LUMC), Anneke ten Brinke (MCL), Jasper Kappen (FGV), Hans Kroes (MCL), Gert-Jan Braunstahl (FGV), Bas Hilvering (AUMC) en Maarten van Bezouw (UU).
The societal- and patient burden of Living with severe ASThma: impact of treatment with biologics (LAST-project).
Jacob Sont (LUMC), Anneke ten Brinke (MCL).
Real-world effects of dupilumab initiation on patient reported outcome measures in severe asthma.
Lianne ten Have (MCL), Kim de Jong (MCL), Hans Kroes (MCL), Fleur Meulmeester (LUMC), Karin Fieten (NAD), Anneke ten Brinke (MCL), Jacob Sont (LUMC).
Real-world evaluation of dupilumab treatment in adults with severe allergic asthma.
Pieter-Paul Hekking (FGV), Tuba Kaya (FGV).
The real-world effect of tezepelumab on patient-centered outcomes in addition to clinical outcomes in patients with severe asthma (AESTHETE).
Fleur Meulmeester (LUMC), Lianne ten Have (MCL), Hans Kroes (MCL), Jacob Sont (LUMC), Anneke ten Brinke (MCL).
Changes In Medication burden after the start of Biologics in patients with severe Asthma (CIMBA study).
Mirjam van Velzen (CMC), Saar van Nederveen (Haga), Katrien Eger (UZA), Hans Kroes (MCL).